Plasma levels of primidone and its metabolite phenobarbital: Effect of age and associated therapy

D. Battino, G. Avanzini, L. Bossi, D. Croci, C. Cusi, C. Gomeni, A. Moise

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The effects of age and associated therapy on plasma primidone (PRM) and derived phenobarbital (PB) concentrations, and on plasma concentrations-to-PRM dose ratios (L/D ratio) were evaluated retrospectively from 408 consecutive PRM and derived PB determinations in 238 chronically treated epileptic patients (153 children and adolescents between 5 months and 15 years of age and 85 adults between 16 and 55 years of age). The correlation between PRM administered and both plasma PRM and derived PB levels was significant; the correlation between PRM and PB plasma levels was also significant, but the scatter of values for the linear regressions was such that the relationship had no predictive value. Significant differences in mean plasma PRM and PB L/D ratios were found between patients aged 0-3 years, 4-9 years, 10-15 years, and adults (16, 55 years), with higher values in the older groups. The PB/PRM concentration ratios were significantly lower in children than in adolescents and adults. Concomitant treatment with carbamazepine affected PRM disposition and led to increased L/D ratios for PB and decreased L/D ratios for PRM, whereas phenytoin increased the L/D ratios for PB without any significant change in the L/D ratios for PRM. The variability in the results indicates the need for routine monitoring of PRM and derived PB plasma levels, particularly in pediatric populations, in order to tailor the dose to each patient.

Original languageEnglish
Pages (from-to)73-79
Number of pages7
JournalTherapeutic Drug Monitoring
Volume5
Issue number1
Publication statusPublished - 1983

Fingerprint

Primidone
Phenobarbital
Metabolites
Plasmas
Therapeutics
Pediatrics
Carbamazepine
Phenytoin
Linear regression

Keywords

  • Anticonvulsants
  • Children
  • Drug interaction
  • Drug monitoring
  • Plasma concentrations
  • Primidone

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Public Health, Environmental and Occupational Health

Cite this

Battino, D., Avanzini, G., Bossi, L., Croci, D., Cusi, C., Gomeni, C., & Moise, A. (1983). Plasma levels of primidone and its metabolite phenobarbital: Effect of age and associated therapy. Therapeutic Drug Monitoring, 5(1), 73-79.

Plasma levels of primidone and its metabolite phenobarbital : Effect of age and associated therapy. / Battino, D.; Avanzini, G.; Bossi, L.; Croci, D.; Cusi, C.; Gomeni, C.; Moise, A.

In: Therapeutic Drug Monitoring, Vol. 5, No. 1, 1983, p. 73-79.

Research output: Contribution to journalArticle

Battino, D, Avanzini, G, Bossi, L, Croci, D, Cusi, C, Gomeni, C & Moise, A 1983, 'Plasma levels of primidone and its metabolite phenobarbital: Effect of age and associated therapy', Therapeutic Drug Monitoring, vol. 5, no. 1, pp. 73-79.
Battino, D. ; Avanzini, G. ; Bossi, L. ; Croci, D. ; Cusi, C. ; Gomeni, C. ; Moise, A. / Plasma levels of primidone and its metabolite phenobarbital : Effect of age and associated therapy. In: Therapeutic Drug Monitoring. 1983 ; Vol. 5, No. 1. pp. 73-79.
@article{9c82017a55754b0aa59a59fe54435634,
title = "Plasma levels of primidone and its metabolite phenobarbital: Effect of age and associated therapy",
abstract = "The effects of age and associated therapy on plasma primidone (PRM) and derived phenobarbital (PB) concentrations, and on plasma concentrations-to-PRM dose ratios (L/D ratio) were evaluated retrospectively from 408 consecutive PRM and derived PB determinations in 238 chronically treated epileptic patients (153 children and adolescents between 5 months and 15 years of age and 85 adults between 16 and 55 years of age). The correlation between PRM administered and both plasma PRM and derived PB levels was significant; the correlation between PRM and PB plasma levels was also significant, but the scatter of values for the linear regressions was such that the relationship had no predictive value. Significant differences in mean plasma PRM and PB L/D ratios were found between patients aged 0-3 years, 4-9 years, 10-15 years, and adults (16, 55 years), with higher values in the older groups. The PB/PRM concentration ratios were significantly lower in children than in adolescents and adults. Concomitant treatment with carbamazepine affected PRM disposition and led to increased L/D ratios for PB and decreased L/D ratios for PRM, whereas phenytoin increased the L/D ratios for PB without any significant change in the L/D ratios for PRM. The variability in the results indicates the need for routine monitoring of PRM and derived PB plasma levels, particularly in pediatric populations, in order to tailor the dose to each patient.",
keywords = "Anticonvulsants, Children, Drug interaction, Drug monitoring, Plasma concentrations, Primidone",
author = "D. Battino and G. Avanzini and L. Bossi and D. Croci and C. Cusi and C. Gomeni and A. Moise",
year = "1983",
language = "English",
volume = "5",
pages = "73--79",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Plasma levels of primidone and its metabolite phenobarbital

T2 - Effect of age and associated therapy

AU - Battino, D.

AU - Avanzini, G.

AU - Bossi, L.

AU - Croci, D.

AU - Cusi, C.

AU - Gomeni, C.

AU - Moise, A.

PY - 1983

Y1 - 1983

N2 - The effects of age and associated therapy on plasma primidone (PRM) and derived phenobarbital (PB) concentrations, and on plasma concentrations-to-PRM dose ratios (L/D ratio) were evaluated retrospectively from 408 consecutive PRM and derived PB determinations in 238 chronically treated epileptic patients (153 children and adolescents between 5 months and 15 years of age and 85 adults between 16 and 55 years of age). The correlation between PRM administered and both plasma PRM and derived PB levels was significant; the correlation between PRM and PB plasma levels was also significant, but the scatter of values for the linear regressions was such that the relationship had no predictive value. Significant differences in mean plasma PRM and PB L/D ratios were found between patients aged 0-3 years, 4-9 years, 10-15 years, and adults (16, 55 years), with higher values in the older groups. The PB/PRM concentration ratios were significantly lower in children than in adolescents and adults. Concomitant treatment with carbamazepine affected PRM disposition and led to increased L/D ratios for PB and decreased L/D ratios for PRM, whereas phenytoin increased the L/D ratios for PB without any significant change in the L/D ratios for PRM. The variability in the results indicates the need for routine monitoring of PRM and derived PB plasma levels, particularly in pediatric populations, in order to tailor the dose to each patient.

AB - The effects of age and associated therapy on plasma primidone (PRM) and derived phenobarbital (PB) concentrations, and on plasma concentrations-to-PRM dose ratios (L/D ratio) were evaluated retrospectively from 408 consecutive PRM and derived PB determinations in 238 chronically treated epileptic patients (153 children and adolescents between 5 months and 15 years of age and 85 adults between 16 and 55 years of age). The correlation between PRM administered and both plasma PRM and derived PB levels was significant; the correlation between PRM and PB plasma levels was also significant, but the scatter of values for the linear regressions was such that the relationship had no predictive value. Significant differences in mean plasma PRM and PB L/D ratios were found between patients aged 0-3 years, 4-9 years, 10-15 years, and adults (16, 55 years), with higher values in the older groups. The PB/PRM concentration ratios were significantly lower in children than in adolescents and adults. Concomitant treatment with carbamazepine affected PRM disposition and led to increased L/D ratios for PB and decreased L/D ratios for PRM, whereas phenytoin increased the L/D ratios for PB without any significant change in the L/D ratios for PRM. The variability in the results indicates the need for routine monitoring of PRM and derived PB plasma levels, particularly in pediatric populations, in order to tailor the dose to each patient.

KW - Anticonvulsants

KW - Children

KW - Drug interaction

KW - Drug monitoring

KW - Plasma concentrations

KW - Primidone

UR - http://www.scopus.com/inward/record.url?scp=0020674124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020674124&partnerID=8YFLogxK

M3 - Article

C2 - 6845402

AN - SCOPUS:0020674124

VL - 5

SP - 73

EP - 79

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -